-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on April 20
The prices of these Chinese medicines are rising
Yesterday, the Pharmaceutical News Agency released the ranking list of Chinese medicinal materials price increase as of April 18 in Bozhou market.
Among them, the monthly price increase rate exceeded 100%, such as gecko, acacia bean, and crane louse.
Among them, the monthly price increase rate exceeded 100%, such as gecko, acacia bean, and crane louse.
(Photo source: See the end of the article for the complete form of Yaotong.
com)
com)
Among them, the gecko has the largest increase, and the three specifications are among the top three in the price increase list.
The current prices of the small pair, medium pair, and large pair are 80/kg, 90/kg, and 100/kg, respectively, and the monthly increases are respectively.
They were 220.
0%, 157.
1%, and 138.
1%.
The current prices of the small pair, medium pair, and large pair are 80/kg, 90/kg, and 100/kg, respectively, and the monthly increases are respectively.
They were 220.
0%, 157.
1%, and 138.
1%.
It is understood that gecko is a second-class protected animal in my country and has related protection measures.
Due to its better medicinal effects, market demand has increased year by year, and prices have been rising year after year due to limited resources.
At present, the domestic model of gecko has not yet been explored and matured and has not yet formed a certain scale.
The market is mainly imported, from Thailand, Indonesia, Vietnam and other places.
Due to its better medicinal effects, market demand has increased year by year, and prices have been rising year after year due to limited resources.
At present, the domestic model of gecko has not yet been explored and matured and has not yet formed a certain scale.
The market is mainly imported, from Thailand, Indonesia, Vietnam and other places.
In addition, the recent price of comfrey is also increasing rapidly, the price has risen by 83.
3% in the past week, and the current price of hard seedlings is 55 yuan/kg.
The market demand for comfrey has been increasing in recent years.
Due to the special growing environment and the inability to grow it at home, the contradiction between supply and demand in the domestic market has become increasingly obvious.
At present, the market mainly relies on imports.
It is speculated that prices will continue to rise in the future.
3% in the past week, and the current price of hard seedlings is 55 yuan/kg.
The market demand for comfrey has been increasing in recent years.
Due to the special growing environment and the inability to grow it at home, the contradiction between supply and demand in the domestic market has become increasingly obvious.
At present, the market mainly relies on imports.
It is speculated that prices will continue to rise in the future.
The price of psoralen is due to many years of low prices, coupled with the recent obstruction of incoming goods at ports, the military coup in Myanmar, the main production area, and the lack of goods by those who have the goods, which have led to the price increase.
However, once the situation in Myanmar eases, the tension between supply and demand will change.
The price of psoralen on the market is between 15 and 18 yuan due to the different content and quality.
However, once the situation in Myanmar eases, the tension between supply and demand will change.
The price of psoralen on the market is between 15 and 18 yuan due to the different content and quality.
Of course, as a market phenomenon, the price of medicinal materials has risen and fallen.
Recently, the prices of medicinal materials such as Lonicera japonica, Chonglou, and Lily have fallen to a certain extent due to oversupply.
Recently, the prices of medicinal materials such as Lonicera japonica, Chonglou, and Lily have fallen to a certain extent due to oversupply.
The Chinese medicine market continues to improve
According to the big data analysis of the pharmaceutical industry in Tiandi Yuntu, in terms of the overall trend of the market price of Chinese medicinal materials in 2021, the price of Chinese medicinal materials at the beginning of 2021 is compared with the end of 2020, and from December 1, 2020 to March 1, 2021.
The 200 index showed a trend of stable first and then accelerated upward.
The 200 index showed a trend of stable first and then accelerated upward.
In March 2021, the World of Chinese Medicinal Materials has monitored the rise and fall of 365 commonly used Chinese medicinal materials.
As many as 127 varieties have risen, accounting for 35.
77%; there are only 19 varieties that have fallen, accounting for 5.
35%, giving feedback on the entire line of Chinese medicinal materials.
The fundamentals of the rise.
As many as 127 varieties have risen, accounting for 35.
77%; there are only 19 varieties that have fallen, accounting for 5.
35%, giving feedback on the entire line of Chinese medicinal materials.
The fundamentals of the rise.
There are many factors that affect the price of Chinese herbal medicines.
Home-grown medicinal materials will rebound due to long-term low prices in the market.
Such medicinal materials include galangal, angelica, dangshen, tree peony peel, white peony root, and polyporus umbellatus.
With the decrease of resources, the market of wild medicinal materials will continue to improve, such as atractylodes, white fresh skin, and Weilingxian.
Such medicinal materials include galangal, angelica, dangshen, tree peony peel, white peony root, and polyporus umbellatus.
With the decrease of resources, the market of wild medicinal materials will continue to improve, such as atractylodes, white fresh skin, and Weilingxian.
The impact of natural disasters on the price of Chinese medicinal materials is also very obvious.
Some medicinal materials that are susceptible to low temperature damage, drought, and floods are worth noting, such as wild jujube kernels, cypress kernels, bitter almonds, and forsythia.
The medicinal materials that mainly rely on imports will also be affected by import channels, such as gecko, comfrey, and psoralen mentioned above.
Some medicinal materials that are susceptible to low temperature damage, drought, and floods are worth noting, such as wild jujube kernels, cypress kernels, bitter almonds, and forsythia.
The medicinal materials that mainly rely on imports will also be affected by import channels, such as gecko, comfrey, and psoralen mentioned above.
In addition, it is worth noting that the 2020 edition of the Pharmacopoeia is fully implemented, and 33 kinds of banned pesticides must not be detected for Chinese medicine.
This poses a higher challenge to relevant pharmaceutical companies, and the Chinese medicine industry has therefore ushered in major changes.
Under the stricter requirements of the new version of the Pharmacopoeia, those medicinal materials that are qualified for pesticide residues will also usher in a wave of price increases.
Such as ginseng with low pesticide residues, qualified Peucedanum chinensis, new coptis with high content, wild Qianghuo, Baiziren with aflatoxin and so on.
This poses a higher challenge to relevant pharmaceutical companies, and the Chinese medicine industry has therefore ushered in major changes.
Under the stricter requirements of the new version of the Pharmacopoeia, those medicinal materials that are qualified for pesticide residues will also usher in a wave of price increases.
Such as ginseng with low pesticide residues, qualified Peucedanum chinensis, new coptis with high content, wild Qianghuo, Baiziren with aflatoxin and so on.
According to the analysis of the World of Chinese Medicinal Materials, at least in April, the price of Chinese herbal medicines in China will still face great upward pressure.
If weather factors such as extreme "back spring cold" occur again, the related fruit and kernel varieties will not rule out a skyrocket.
If weather factors such as extreme "back spring cold" occur again, the related fruit and kernel varieties will not rule out a skyrocket.
However, from a fundamental point of view, although the production and demand of Chinese medicinal materials will both decline in 2020, as of December 2020, the total inventory has reached more than 2.
211 million tons, which is enough to support the start of new production in April.
Therefore, although the market for Chinese medicinal materials will rise rapidly in stages in 2021, it is difficult to see serious surges in 2009 and 2011.
The market will run at a high level throughout the year, but the increase will be much more moderate.
211 million tons, which is enough to support the start of new production in April.
Therefore, although the market for Chinese medicinal materials will rise rapidly in stages in 2021, it is difficult to see serious surges in 2009 and 2011.
The market will run at a high level throughout the year, but the increase will be much more moderate.
Far-reaching
The price increase of Chinese medicinal materials has a lagging effect on the terminal market.
I believe that the general price increase of Chinese medicinal materials will directly affect downstream pharmaceutical companies in the future, and have a certain impact on Chinese herbal medicine decoction pieces and Chinese medicine preparation companies.
I believe that the general price increase of Chinese medicinal materials will directly affect downstream pharmaceutical companies in the future, and have a certain impact on Chinese herbal medicine decoction pieces and Chinese medicine preparation companies.
The price increase of medicinal materials and the high standards of the pharmacopoeia will increase the cost for decoction pieces companies, and the reshuffle of the decoction pieces industry will accelerate.
This is good for leading companies.
It is conducive to the standardized development of the market and the increase in concentration.
Large-scale decoction pieces factories have more room for bargaining, are able to upgrade their standards to meet the requirements of national supervision, and can adapt to changes in the environment more quickly.
The life of a relatively small decoction piece factory will be more difficult.
This is good for leading companies.
It is conducive to the standardized development of the market and the increase in concentration.
Large-scale decoction pieces factories have more room for bargaining, are able to upgrade their standards to meet the requirements of national supervision, and can adapt to changes in the environment more quickly.
The life of a relatively small decoction piece factory will be more difficult.
At present, my country's traditional Chinese medicine decoction pieces market has a scale of more than 200 billion yuan, but there are probably more than 1,000 Chinese medicine decoction pieces processing companies, and the market share of leading enterprises is not high.
According to the report of the Prospective Industry Research Institute, there are currently more than 1,000 Chinese herbal medicine decoction pieces manufacturing enterprises in my country, but most of the production enterprises are small in scale, produce many varieties, and the industry market concentration is low.
According to the report of the Prospective Industry Research Institute, there are currently more than 1,000 Chinese herbal medicine decoction pieces manufacturing enterprises in my country, but most of the production enterprises are small in scale, produce many varieties, and the industry market concentration is low.
In 2019, Yunnan Baiyao, Tongrentang, and Kangmei Pharmaceutical, the major listed companies of traditional Chinese medicine decoction pieces, exceeded 10 billion yuan in operating income, respectively 29.
665 billion yuan, 13.
277 billion yuan and 11.
446 billion yuan.
The operating income of the remaining listed companies is less than 5 billion yuan.
665 billion yuan, 13.
277 billion yuan and 11.
446 billion yuan.
The operating income of the remaining listed companies is less than 5 billion yuan.
In addition, for Chinese patent medicine companies, the increase in the price of Chinese medicinal materials also means an increase in business costs.
In addition, due to the high standard requirements for the quality and traceability of Chinese herbal medicines in relevant policies such as Chinese herbal medicine formula granules, many domestic listed pharmaceutical companies have established Chinese herbal medicine companies or product processing bases, acquired Chinese herbal medicine companies equity, and established Chinese herbal medicine merger management funds.
The way to get involved in Chinese herbal medicines, to realize the layout in advance, and to seize the opportunity after the industry's integration and upgrading.
In addition, due to the high standard requirements for the quality and traceability of Chinese herbal medicines in relevant policies such as Chinese herbal medicine formula granules, many domestic listed pharmaceutical companies have established Chinese herbal medicine companies or product processing bases, acquired Chinese herbal medicine companies equity, and established Chinese herbal medicine merger management funds.
The way to get involved in Chinese herbal medicines, to realize the layout in advance, and to seize the opportunity after the industry's integration and upgrading.
For example, in December 2019, a subsidiary of China Traditional Chinese Medicine purchased a 51% stake in Gansu Longzhong Pharmaceutical for approximately 135 million yuan.
In March 2020, Shengshi Baicao was acquired 80% of the equity by Ping An Tsumura.
In March 2020, Shengshi Baicao was acquired 80% of the equity by Ping An Tsumura.
As the country attaches importance to the development of the Chinese medicine industry, many Chinese medicine companies have ushered in new development opportunities, but the prerequisite for development is standardization and high standards.
In medicine is essential Chinese medicine, the price trend worth noting.
In medicine is essential Chinese medicine, the price trend worth noting.
A list of price increases for Chinese medicinal materials is attached below:
Medical Network News on April 20
The prices of these Chinese medicines are rising
Yesterday, the Pharmaceutical News Agency released the ranking list of Chinese medicinal materials price increase as of April 18 in Bozhou market.
Among them, the monthly price increase rate exceeded 100%, such as gecko, acacia bean, and crane louse.
Among them, the monthly price increase rate exceeded 100%, such as gecko, acacia bean, and crane louse.
(Photo source: See the end of the article for the complete form of Yaotong.
com)
com)
Among them, the gecko has the largest increase, and the three specifications are among the top three in the price increase list.
The current prices of the small pair, medium pair, and large pair are 80/kg, 90/kg, and 100/kg, respectively, and the monthly increases are respectively.
They were 220.
0%, 157.
1%, and 138.
1%.
The current prices of the small pair, medium pair, and large pair are 80/kg, 90/kg, and 100/kg, respectively, and the monthly increases are respectively.
They were 220.
0%, 157.
1%, and 138.
1%.
It is understood that gecko is a second-class protected animal in my country and has related protection measures.
Due to its better medicinal effects, market demand has increased year by year, and prices have been rising year after year due to limited resources.
At present, the domestic model of gecko has not yet been explored and matured and has not yet formed a certain scale.
The market is mainly imported, from Thailand, Indonesia, Vietnam and other places.
Due to its better medicinal effects, market demand has increased year by year, and prices have been rising year after year due to limited resources.
At present, the domestic model of gecko has not yet been explored and matured and has not yet formed a certain scale.
The market is mainly imported, from Thailand, Indonesia, Vietnam and other places.
In addition, the recent price of comfrey is also increasing rapidly, the price has risen by 83.
3% in the past week, and the current price of hard seedlings is 55 yuan/kg.
The market demand for comfrey has been increasing in recent years.
Due to the special growing environment and the inability to grow it at home, the contradiction between supply and demand in the domestic market has become increasingly obvious.
At present, the market mainly relies on imports.
It is speculated that prices will continue to rise in the future.
3% in the past week, and the current price of hard seedlings is 55 yuan/kg.
The market demand for comfrey has been increasing in recent years.
Due to the special growing environment and the inability to grow it at home, the contradiction between supply and demand in the domestic market has become increasingly obvious.
At present, the market mainly relies on imports.
It is speculated that prices will continue to rise in the future.
The price of psoralen is due to many years of low prices, coupled with the recent obstruction of incoming goods at ports, the military coup in Myanmar, the main production area, and the lack of goods by those who have the goods, which have led to the price increase.
However, once the situation in Myanmar eases, the tension between supply and demand will change.
The price of psoralen on the market is between 15 and 18 yuan due to the different content and quality.
However, once the situation in Myanmar eases, the tension between supply and demand will change.
The price of psoralen on the market is between 15 and 18 yuan due to the different content and quality.
Of course, as a market phenomenon, the price of medicinal materials has risen and fallen.
Recently, the prices of medicinal materials such as Lonicera japonica, Chonglou, and Lily have fallen to a certain extent due to oversupply.
Recently, the prices of medicinal materials such as Lonicera japonica, Chonglou, and Lily have fallen to a certain extent due to oversupply.
The Chinese medicine market continues to improve
According to the big data analysis of the pharmaceutical industry in Tiandi Yuntu, in terms of the overall trend of the market price of Chinese medicinal materials in 2021, the price of Chinese medicinal materials at the beginning of 2021 is compared with the end of 2020, and from December 1, 2020 to March 1, 2021.
The 200 index showed a trend of stable first and then accelerated upward.
The 200 index showed a trend of stable first and then accelerated upward.
20213，365，127，35.
77%；19，5.
35%，。
77%；19，5.
35%，。
。
，、、、、、。，，、、。
，、，、、、。，、、。
，2020，33。，。，。、、、、。
，4，。“”，。
，2020，202012，221.
1，4。，2021，2009、2011，，。
1，4。，2021，2009、2011，，。
，，，。
The price increase of medicinal materials and the high standards of the pharmacopoeia will increase the cost for decoction pieces companies, and the reshuffle of the decoction pieces industry will accelerate.
This is good for leading companies.
It is conducive to the standardized development of the market and the increase in concentration.
Large-scale decoction pieces factories have more room for bargaining, are able to upgrade their standards to meet the requirements of national supervision, and can adapt to changes in the environment more quickly.
The life of a relatively small decoction piece factory will be more difficult.
This is good for leading companies.
It is conducive to the standardized development of the market and the increase in concentration.
Large-scale decoction pieces factories have more room for bargaining, are able to upgrade their standards to meet the requirements of national supervision, and can adapt to changes in the environment more quickly.
The life of a relatively small decoction piece factory will be more difficult.
At present, my country's traditional Chinese medicine decoction pieces market has a scale of more than 200 billion yuan, but there are probably more than 1,000 Chinese medicine decoction pieces processing companies, and the market share of leading enterprises is not high.
According to the report of the Prospective Industry Research Institute, there are currently more than 1,000 Chinese herbal medicine decoction pieces manufacturing enterprises in my country, but most of the production enterprises are small in scale, produce many varieties, and the industry market concentration is low.
According to the report of the Prospective Industry Research Institute, there are currently more than 1,000 Chinese herbal medicine decoction pieces manufacturing enterprises in my country, but most of the production enterprises are small in scale, produce many varieties, and the industry market concentration is low.
In 2019, Yunnan Baiyao, Tongrentang, and Kangmei Pharmaceutical, the major listed companies of traditional Chinese medicine decoction pieces, exceeded 10 billion yuan in operating income, respectively 29.
665 billion yuan, 13.
277 billion yuan and 11.
446 billion yuan.
The operating income of the remaining listed companies is less than 5 billion yuan.
665 billion yuan, 13.
277 billion yuan and 11.
446 billion yuan.
The operating income of the remaining listed companies is less than 5 billion yuan.
In addition, for Chinese patent medicine companies, the increase in the price of Chinese medicinal materials also means an increase in business costs.
In addition, due to the high standard requirements for the quality and traceability of Chinese herbal medicines in relevant policies such as Chinese herbal medicine formula granules, many domestic listed pharmaceutical companies have established Chinese herbal medicine companies or product processing bases, acquired Chinese herbal medicine companies equity, and established Chinese herbal medicine merger management funds.
The way to get involved in Chinese herbal medicines, to realize the layout in advance, and to seize the opportunity after the industry's integration and upgrading.
In addition, due to the high standard requirements for the quality and traceability of Chinese herbal medicines in relevant policies such as Chinese herbal medicine formula granules, many domestic listed pharmaceutical companies have established Chinese herbal medicine companies or product processing bases, acquired Chinese herbal medicine companies equity, and established Chinese herbal medicine merger management funds.
The way to get involved in Chinese herbal medicines, to realize the layout in advance, and to seize the opportunity after the industry's integration and upgrading.
For example, in December 2019, a subsidiary of China Traditional Chinese Medicine purchased a 51% stake in Gansu Longzhong Pharmaceutical for approximately 135 million yuan.
In March 2020, Shengshi Baicao was acquired 80% of the equity by Ping An Tsumura.
In March 2020, Shengshi Baicao was acquired 80% of the equity by Ping An Tsumura.
As the country attaches importance to the development of the Chinese medicine industry, many Chinese medicine companies have ushered in new development opportunities, but the prerequisite for development is standardization and high standards.
In medicine is essential Chinese medicine, the price trend worth noting.
In medicine is essential Chinese medicine, the price trend worth noting.
A list of price increases for Chinese medicinal materials is attached below:
Medical Network News on April 20
The prices of these Chinese medicines are rising
The prices of these Chinese medicines are rising Yesterday, the Pharmaceutical News Agency released the ranking list of Chinese medicinal materials price increase as of April 18 in Bozhou market.
Among them, the monthly price increase rate exceeded 100%, such as gecko, acacia bean, and crane louse.
Among them, the monthly price increase rate exceeded 100%, such as gecko, acacia bean, and crane louse.
(Photo source: See the end of the article for the complete form of Yaotong.
com)
com)
Among them, the gecko has the largest increase, and the three specifications are among the top three in the price increase list.
The current prices of the small pair, medium pair, and large pair are 80/kg, 90/kg, and 100/kg, respectively, and the monthly increases are respectively.
They were 220.
0%, 157.
1%, and 138.
1%.
The current prices of the small pair, medium pair, and large pair are 80/kg, 90/kg, and 100/kg, respectively, and the monthly increases are respectively.
They were 220.
0%, 157.
1%, and 138.
1%.
It is understood that gecko is a second-class protected animal in my country and has related protection measures.
Due to its better medicinal effects, market demand has increased year by year, and prices have been rising year after year due to limited resources.
At present, the domestic model of gecko has not yet been explored and matured and has not yet formed a certain scale.
The market is mainly imported, from Thailand, Indonesia, Vietnam and other places.
Due to its better medicinal effects, market demand has increased year by year, and prices have been rising year after year due to limited resources.
At present, the domestic model of gecko has not yet been explored and matured and has not yet formed a certain scale.
The market is mainly imported, from Thailand, Indonesia, Vietnam and other places.
In addition, the recent price of comfrey is also increasing rapidly, the price has risen by 83.
3% in the past week, and the current price of hard seedlings is 55 yuan/kg.
The market demand for comfrey has been increasing in recent years.
Due to the special growing environment and the inability to grow it at home, the contradiction between supply and demand in the domestic market has become increasingly obvious.
At present, the market mainly relies on imports.
It is speculated that prices will continue to rise in the future.
3% in the past week, and the current price of hard seedlings is 55 yuan/kg.
The market demand for comfrey has been increasing in recent years.
Due to the special growing environment and the inability to grow it at home, the contradiction between supply and demand in the domestic market has become increasingly obvious.
At present, the market mainly relies on imports.
It is speculated that prices will continue to rise in the future.
The price of psoralen is due to many years of low prices, coupled with the recent obstruction of incoming goods at ports, the military coup in Myanmar, the main production area, and the lack of goods by those who have the goods, which have led to the price increase.
However, once the situation in Myanmar eases, the tension between supply and demand will change.
The price of psoralen on the market is between 15 and 18 yuan due to the different content and quality.
However, once the situation in Myanmar eases, the tension between supply and demand will change.
The price of psoralen on the market is between 15 and 18 yuan due to the different content and quality.
Of course, as a market phenomenon, the price of medicinal materials has risen and fallen.
Recently, the prices of medicinal materials such as Lonicera japonica, Chonglou, and Lily have fallen to a certain extent due to oversupply.
Recently, the prices of medicinal materials such as Lonicera japonica, Chonglou, and Lily have fallen to a certain extent due to oversupply.
The Chinese medicine market continues to improve
The Chinese medicine market continues to improve According to the big data analysis of the pharmaceutical industry in Tiandi Yuntu, in terms of the overall trend of the market price of Chinese medicinal materials in 2021, the price of Chinese medicinal materials at the beginning of 2021 is compared with the end of 2020, and from December 1, 2020 to March 1, 2021.
The 200 index showed a trend of stable first and then accelerated upward.
The 200 index showed a trend of stable first and then accelerated upward.
In March 2021, the World of Chinese Medicinal Materials has monitored the rise and fall of 365 commonly used Chinese medicinal materials.
As many as 127 varieties have risen, accounting for 35.
77%; there are only 19 varieties that have fallen, accounting for 5.
35%, giving feedback on the entire line of Chinese medicinal materials.
The fundamentals of the rise.
As many as 127 varieties have risen, accounting for 35.
77%; there are only 19 varieties that have fallen, accounting for 5.
35%, giving feedback on the entire line of Chinese medicinal materials.
The fundamentals of the rise.
There are many factors that affect the price of Chinese herbal medicines.
Home-grown medicinal materials will rebound due to long-term low prices in the market.
Such medicinal materials include galangal, angelica, dangshen, tree peony peel, white peony root, and polyporus umbellatus.
With the decrease of resources, the market of wild medicinal materials will continue to improve, such as atractylodes, white fresh skin, and Weilingxian.
Such medicinal materials include galangal, angelica, dangshen, tree peony peel, white peony root, and polyporus umbellatus.
With the decrease of resources, the market of wild medicinal materials will continue to improve, such as atractylodes, white fresh skin, and Weilingxian.
The impact of natural disasters on the price of Chinese medicinal materials is also very obvious.
Some medicinal materials that are susceptible to low temperature damage, drought, and floods are worth noting, such as wild jujube kernels, cypress kernels, bitter almonds, and forsythia.
The medicinal materials that mainly rely on imports will also be affected by import channels, such as gecko, comfrey, and psoralen mentioned above.
Some medicinal materials that are susceptible to low temperature damage, drought, and floods are worth noting, such as wild jujube kernels, cypress kernels, bitter almonds, and forsythia.
The medicinal materials that mainly rely on imports will also be affected by import channels, such as gecko, comfrey, and psoralen mentioned above.
In addition, it is worth noting that the 2020 edition of the Pharmacopoeia is fully implemented, and 33 kinds of banned pesticides must not be detected for Chinese medicine.
This poses a higher challenge to relevant pharmaceutical companies, and the Chinese medicine industry has therefore ushered in major changes.
Under the stricter requirements of the new version of the Pharmacopoeia, those medicinal materials that are qualified for pesticide residues will also usher in a wave of price increases.
Such as ginseng with low pesticide residues, qualified Peucedanum chinensis, new coptis with high content, wild Qianghuo, Baiziren with aflatoxin and so on.
This poses a higher challenge to relevant pharmaceutical companies, and the Chinese medicine industry has therefore ushered in major changes.
Under the stricter requirements of the new version of the Pharmacopoeia, those medicinal materials that are qualified for pesticide residues will also usher in a wave of price increases.
Such as ginseng with low pesticide residues, qualified Peucedanum chinensis, new coptis with high content, wild Qianghuo, Baiziren with aflatoxin and so on.
According to the analysis of the World of Chinese Medicinal Materials, at least in April, the price of Chinese herbal medicines in China will still face great upward pressure.
If weather factors such as extreme "back spring cold" occur again, the related fruit and kernel varieties will not rule out a skyrocket.
If weather factors such as extreme "back spring cold" occur again, the related fruit and kernel varieties will not rule out a skyrocket.
However, from a fundamental point of view, although the production and demand of Chinese medicinal materials will both decline in 2020, as of December 2020, the total inventory has reached more than 2.
211 million tons, which is enough to support the start of new production in April.
Therefore, although the market for Chinese medicinal materials will rise rapidly in stages in 2021, it is difficult to see serious surges in 2009 and 2011.
The market will run at a high level throughout the year, but the increase will be much more moderate.
211 million tons, which is enough to support the start of new production in April.
Therefore, although the market for Chinese medicinal materials will rise rapidly in stages in 2021, it is difficult to see serious surges in 2009 and 2011.
The market will run at a high level throughout the year, but the increase will be much more moderate.
Far-reaching
Far-reaching The price increase of Chinese medicinal materials has a lagging effect on the terminal market.
I believe that the general price increase of Chinese medicinal materials will directly affect downstream pharmaceutical companies in the future, and have a certain impact on Chinese herbal medicine decoction pieces and Chinese medicine preparation companies.
I believe that the general price increase of Chinese medicinal materials will directly affect downstream pharmaceutical companies in the future, and have a certain impact on Chinese herbal medicine decoction pieces and Chinese medicine preparation companies.
The price increase of medicinal materials and the high standards of the pharmacopoeia will increase the cost for decoction pieces companies, and the reshuffle of the decoction pieces industry will accelerate.
This is good for leading companies.
It is conducive to the standardized development of the market and the increase in concentration.
Large-scale decoction pieces factories have more room for bargaining, are able to upgrade their standards to meet the requirements of national supervision, and can adapt to changes in the environment more quickly.
The life of a relatively small decoction piece factory will be more difficult.
Standard Standard StandardThis is good for leading companies.
It is conducive to the standardized development of the market and the increase in concentration.
Large-scale decoction pieces factories have more room for bargaining, are able to upgrade their standards to meet the requirements of national supervision, and can adapt to changes in the environment more quickly.
The life of a relatively small decoction piece factory will be more difficult.
At present, my country's traditional Chinese medicine decoction pieces market has a scale of more than 200 billion yuan, but there are probably more than 1,000 Chinese medicine decoction pieces processing companies, and the market share of leading enterprises is not high.
According to the report of the Prospective Industry Research Institute, there are currently more than 1,000 Chinese herbal medicine decoction pieces manufacturing enterprises in my country, but most of the production enterprises are small in scale, produce many varieties, and the industry market concentration is low.
According to the report of the Prospective Industry Research Institute, there are currently more than 1,000 Chinese herbal medicine decoction pieces manufacturing enterprises in my country, but most of the production enterprises are small in scale, produce many varieties, and the industry market concentration is low.
In 2019, Yunnan Baiyao, Tongrentang, and Kangmei Pharmaceutical, the major listed companies of traditional Chinese medicine decoction pieces, exceeded 10 billion yuan in operating income, respectively 29.
665 billion yuan, 13.
277 billion yuan and 11.
446 billion yuan.
The operating income of the remaining listed companies is less than 5 billion yuan.
665 billion yuan, 13.
277 billion yuan and 11.
446 billion yuan.
The operating income of the remaining listed companies is less than 5 billion yuan.
In addition, for Chinese patent medicine companies, the increase in the price of Chinese medicinal materials also means an increase in business costs.
In addition, due to the high standard requirements for the quality and traceability of Chinese herbal medicines in relevant policies such as Chinese herbal medicine formula granules, many domestic listed pharmaceutical companies have established Chinese herbal medicine companies or product processing bases, acquired Chinese herbal medicine companies equity, and established Chinese herbal medicine merger management funds.
The way to get involved in Chinese herbal medicines, to realize the layout in advance, and to seize the opportunity after the industry's integration and upgrading.
Chinese herbal medicinesChinese herbal medicinesChinese herbal medicinesIn addition, due to the high standard requirements for the quality and traceability of Chinese herbal medicines in relevant policies such as Chinese herbal medicine formula granules, many domestic listed pharmaceutical companies have established Chinese herbal medicine companies or product processing bases, acquired Chinese herbal medicine companies equity, and established Chinese herbal medicine merger management funds.
The way to get involved in Chinese herbal medicines, to realize the layout in advance, and to seize the opportunity after the industry's integration and upgrading.
For example, in December 2019, a subsidiary of China Traditional Chinese Medicine purchased a 51% stake in Gansu Longzhong Pharmaceutical for approximately 135 million yuan.
In March 2020, Shengshi Baicao was acquired 80% of the equity by Ping An Tsumura.
In March 2020, Shengshi Baicao was acquired 80% of the equity by Ping An Tsumura.
As the country attaches importance to the development of the Chinese medicine industry, many Chinese medicine companies have ushered in new development opportunities, but the prerequisite for development is standardization and high standards.
In medicine is essential Chinese medicine, the price trend worth noting.
Pharmaceutical medicine pharmaceutical companies business enterprises herbs medicinal herbsIn medicine is essential Chinese medicine, the price trend worth noting.
A list of price increases for Chinese medicinal materials is attached below:
